News from the FDA/CDC

FDA approves rivaroxaban for VTE prevention in hospitalized, acutely ill patients


 

The Food and Drug Administration has approved rivaroxaban (Xarelto) for the prevention of venous thromboembolism (VTE) in hospitalized, acutely ill patients at risk for thromboembolic complications who do not have a high bleeding risk, according to a release from Janssen.

FDA icon

FDA approval for the new indication is based on results from the phase 3 MAGELLAN and MARINER trials, which included more than 20,000 hospitalized, acutely ill patients. In MAGELLAN, rivaroxaban demonstrated noninferiority to enoxaparin, a low-molecular-weight heparin, in short-term usage, and it was superior over the long term, compared with short-term enoxaparin followed by placebo.

While VTE and VTE-related deaths were not reduced in MARINER, compared with placebo, patients who received rivaroxaban did see a significantly reduction in symptomatic VTE with a favorable safety profile.

According to the indication, rivaroxaban can be administered to patients during hospitalization and can be continued after discharge for 31-39 days. The safety profile in MAGELLAN and MARINER was consistent with that already seen, with the most common adverse event being bleeding.

The new indication is the eighth for rivaroxaban, the most of any direct oral anticoagulant; six of these are specifically for the treatment, prevention, and reduction in the risk of VTE recurrence.

“With this new approval, Xarelto as an oral-only option now has the potential to change how acutely ill medical patients are managed for the prevention of blood clots, both in the hospital and for an extended period after discharge,” said Alex C. Spyropoulos, MD, of Northwell Health at Lenox Hill Hospital, New York, and a member of the steering committee of the MAGELLAN trial.

Find the full press release on the Janssen website.

Recommended Reading

Myeloma therapies raise cardiovascular risks
Clinician Reviews
Eisenmenger syndrome is a minefield for unwary physicians
Clinician Reviews
Repeat VTE risk heightened in HIV patients
Clinician Reviews
Andexanet alfa effectively reverses factor Xa inhibition
Clinician Reviews
AUGUSTUS: Dual surpasses triple therapy when AFib patients have PCI or ACS
Clinician Reviews
Occurrence of pulmonary embolisms in hospitalized patients nearly doubled during 2004-2015
Clinician Reviews
Rivaroxaban tied to higher GI bleeding than other NOACs
Clinician Reviews
NOACs benefit early stage chronic kidney disease patients
Clinician Reviews
POP AGE shakes up DAPT in elderly
Clinician Reviews
Older IBD patients are most at risk of postdischarge VTE
Clinician Reviews